Research programme: cannabinoid receptor CB2 agonists - Arena Pharmaceuticals

Drug Profile

Research programme: cannabinoid receptor CB2 agonists - Arena Pharmaceuticals

Alternative Names: AR-XYZ

Latest Information Update: 03 May 2016

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteoarthritis; Pain

Most Recent Events

  • 03 May 2016 Discontinued - Preclinical for Pain in USA (PO)
  • 03 May 2016 Discontinued - Early research for Osteoarthritis in USA (PO)
  • 26 Apr 2012 Preclinical trials in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top